NCT04439201 2026-03-18
Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
208 trialsNCT04439292 2026-03-18
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439318 2026-03-18
Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439331 2026-03-18
Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439357 2026-03-18
Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06303167 2026-03-18
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04634552 2026-03-17
MonumenTAL-1
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT04728893 2026-03-16
MK-1026-003
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT04557098 2026-03-12
MajesTEC-1
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT04984551 2026-03-05
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07006506 2026-03-05
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05873205 2026-03-02
Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07441967 2026-03-02
The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT04438382 2026-02-27
Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT03850366 2026-02-24
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
Henry Ford Health System
Phase 2 Recruiting
NCT05005442 2026-02-19
A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02210078 2026-02-17
Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02861417 2026-02-17
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07359859 2026-02-17
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT01949662 2026-02-13
Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01628029 2026-02-04
Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05952804 2026-01-30
IVIG for Infection Prevention After CAR-T-Cell Therapy
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT03032783 2026-01-29
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity
Thomas Jefferson University
Phase 2 Completed
NCT03159702 2026-01-27
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
Medical College of Wisconsin
Phase 2 Completed
NCT06252870 2026-01-26
CY-MET-RIC
Nantes University Hospital
Phase 2 Recruiting
NCT06541067 2026-01-26
POSALLO
Nantes University Hospital
Phase 2 Recruiting
NCT04395222 2026-01-06
Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT04560673 2025-12-31
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT01349101 2025-12-15
A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors
Thomas Jefferson University
Phase 2 Completed
NCT06799195 2025-12-15
PTCYGVHD
University of Nebraska
Phase 2 Recruiting
NCT06465433 2025-12-10
Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
Incyte Corporation
Phase 2 Recruiting
NCT05256537 2025-12-08
OmitMMF
Cedars-Sinai Medical Center
Phase 2 Active not recruiting
NCT06807606 2025-12-04
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04439110 2025-11-21
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439149 2025-11-21
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439188 2025-11-19
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439266 2025-11-19
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439279 2025-11-19
Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439344 2025-11-19
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06510699 2025-11-19
PRAGMATIC
The University of Queensland
Phase 2 Recruiting
NCT04439175 2025-11-18
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04060277 2025-11-14
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
City of Hope Medical Center
Phase 2 Active not recruiting
NCT02710253 2025-11-10
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04439227 2025-10-31
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05529069 2025-10-24
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04112810 2025-10-21
Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease
Medical College of Wisconsin
Phase 2 Completed
NCT03680092 2025-10-02
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
University of California, San Diego
Phase 2 Completed
NCT05579769 2025-10-02
Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT05246670 2025-09-22
PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy
Academic and Community Cancer Research United
Phase 2 Active not recruiting
NCT04439253 2025-09-18
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
National Cancer Institute (NCI)
Phase 2 Active not recruiting